http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2011203323-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
filingDate | 2011-07-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2430a3c2f8091c844ec025d03773901 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9fedcf8a47bd0eddbe33952d9de4a072 |
publicationDate | 2011-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | AU-2011203323-A1 |
titleOfInvention | Apoptosis sensitivity to Apo2L/TRAIL by testing for GalNac-T14 expression in cells/tissues |
abstract | Methods and assays examining expression of one or more biomarkers in a 5 mammalian tissue or cell sample are provided. According to the disclosed methods and assays, detection of the expression of GalNac-T related molecules, such as GalNac-T14 or GalNac-T3, is predictive or indicative that the tissue or cell sample will be sensitive to apoptosis-inducing agents such as Apo2L/TRAIL and anti-DR5 agonist antibodies. Kits and articles 'of 10 manufacture are also provided. 2727342_1 (GHMatters) P78553 AU I |
priorityDate | 2005-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2220.